Genetic Applied sciences (NASDAQ:GENE) inventory rose ~20% on Thursday after the corporate announce the publication of a analysis paper in a journal suggesting geneType’s capacity to detect breast most cancers earlier and supply information for danger stratification.

The paper — which was revealed within the journal Breast Most cancers Analysis and Remedy — studies outcomes from a examine undertaken by the corporate’s scientific crew and researchers at Harvard Medical Faculty and the College of Melbourne.

The examine in contrast geneType’s easy breast most cancers danger evaluation in opposition to a fancy mannequin with extra danger elements and two generally used scientific fashions — Gail and IBIS.

The Australian firm mentioned GeneType outperformed the Gail and IBIS fashions by a major margin and had equal efficiency to the Rosner mannequin with out the necessity to gather a considerably bigger variety of danger elements.

The geneType mannequin contains a very powerful danger elements for breast most cancers prediction — polygenic danger rating, mammographic density and household historical past, the corporate added.

Genetic Applied sciences famous that by utilizing geneType for breast most cancers, girls who would profit most from risk-reducing medicines could be recognized and a major discount in breast most cancers incidence may very well be achieved.

“The publication of this information is a crucial step to assist our reimbursement technique. The constructing record of supportive scientific information together with our funds influence mannequin reveals U.S. payers and insurers that the introduction of the simple to implement geneType danger evaluation take a look at for breast most cancers allows medical doctors to have elevated visibility of at-risk girls,” mentioned CEO Simon Morriss.

The paper used information from the Nurses’ Well being Examine, which included 121,700 feminine registered nurses aged 30 years to 55 years, in response to the corporate.